Eurofins Scientific SE

Equities

ERF

FR0014000MR3

Healthcare Facilities & Services

Market Closed - Euronext Paris Other stock markets 11:37:29 2024-04-23 am EDT			5-day change	1st Jan Change
61.6 ^EUR	+2.19%		+4.16%	+4.44%

Apr. 23	CAC40: up sharply, back over 8100 pts	CF
Apr. 05	CAC40: week ends at half-mast, gold at its zenith	CF

Tranche Update on Eurofins Scientific SE's Equity Buyback Plan announced on October 3, 2022.

December 22, 2022 at 01:15 am EST

From October 3, 2022 to December 3, 2022, the company has repurchased 121,493 shares, representing 0.06% for €7.45 million. With this, the company has completed the repurchase of 121,493 shares, representing 0.06% for €7.45 million under the buyback announced on October 3, 2022.

Latest news about Eurofins Scientific SE

CAC40: up sharply, back over 8100 pts	Apr. 23	CF
CAC40: week ends at half-mast, gold at its zenith	Apr. 05	CF
CAC40: pullback reduced, WStreet +0.7%, Brent at $91, Gold at $233	Apr. 05	CF
CAC40: easily preserves 8,000Pts, NFP has no impact	Apr. 05	CF
CAC40: ends the day balanced after a salvo of statistics	Apr. 04	CF
CAC40: frozen at 8,155, W-Street well disposed, gold at its zenith	Apr. 04	CF
CAC40: indecisive towards 8,160, W-Street climbs back to the top	Apr. 04	CF
EUROFINS SCIENTIFIC : Berenberg raises its price target	Apr. 04	CF
CAC40: up slightly after PMI figures	Apr. 04	CF
Eurofins Scientific to Purchase US-based Ascend Clinical	Apr. 03	MT
Eurofins completes acquisition of Ascend Clinical	Apr. 03	CF
Eurofins Scientific SE acquired Ascend Clinical, LLC.	Apr. 02	CI
CAC40: ends with a balanced performance, helped by the banking sector	Mar. 28	CF
CAC40: all-time high, tackles 8250 resistance level	Mar. 28	CF
European Equities Close Mixed in Monday Trading; Real Estate, Pharmaceutical Stocks Rise	Mar. 11	MT
CAC40: insignificant decline in limited volumes	Mar. 11	CF
Enzymatica Obtains CE Marking for ColdZyme Mouth Spray	Mar. 11	MT
CAC40: zero reaction to US PCE, but February ends on a high note	Feb. 29	CF
CAC40: steady ahead of US inflation figures	Feb. 29	CF
CAC40: frozen at 7.945, heavy sanction on Teleperformance	Feb. 28	CF
CAC40: remains stable despite Teleperformance's fall	Feb. 28	CF
EUROFINS SCIENTIFIC : Lackluster FCF and dividend cut weigh on the share price	Feb. 28
CAC40: up slightly, driven by Bouygues and Alstom	Feb. 27	CF
CAC40: approaches 8,000, Nasdaq solid despite US stats	Feb. 27	CF
CAC40: back above 7,950, tech supports Wall-Street	Feb. 27	CF

Chart Eurofins Scientific SE

Duration

Period

More charts

Company Profile

Eurofins Scientific SE is one of the world's leading providers of bio-analytical services. The group's services are intended to validate the safety, authenticity, origin, identity, and purity of biological substances contained in the environment (water, air, soil, etc.) and in food, pharmaceutical, cosmetic, and hygiene products. At the end of 2023, Eurofins Scientific SE owned a portfolio of over 200,000 analytical methods and had 900 laboratories located throughout the world. Net sales are distributed geographically as follows: Europe (50.7%), North America (38.5%) and other (10.8%).

Sector

Healthcare Facilities & Services

Calendar

2024-04-23 - Q1 2024 Sales and Revenue Release - Trading Update

Related indices

CAC 40 , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

EUROFINS SCIENTIFIC : Lackluster FCF and dividend cut weigh on the share price

February 28, 2024 at 03:42 am EST

More Strategies

Ratings for Eurofins Scientific SE

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

61.6 EUR

Average target price

60 EUR

Spread / Average Target

-2.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
EUROFINS SCIENTIFIC SE	+4.44%	12.37B
CVS HEALTH CORPORATION	-13.25%	87.77B
HCA HEALTHCARE, INC.	+18.01%	82.08B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+11.97%	30.03B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-8.50%	17.08B
FRESENIUS SE & CO. KGAA	-1.46%	16.41B
FRESENIUS MEDICAL CARE AG	+5.11%	12.17B
PURE HEALTH HOLDING	-31.05%	11.89B
DAVITA INC.	+27.83%	11.62B
UNIVERSAL HEALTH SERVICES, INC.	+8.18%	10.85B

Other Healthcare Facilities & Services